Form 4: Exact Sciences Executive Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Exact Sciences' SVP and General Counsel, James Herriott, sold 1,000 shares of common stock for $70 per share under a pre-arranged 10b5-1 trading plan.
Summary
- James Herriott, SVP, General Counsel & Secretary of Exact Sciences Corp (EXAS), reported a transaction.
- The transaction involved the disposition of 1,000 shares of Common Stock.
- The shares were sold at a price of $70 per share.
- The transaction occurred on November 19, 2025.
- This sale was executed pursuant to a Rule 10b5-1 trading plan, which was entered into on March 3, 2025.
- Following this transaction, Mr. Herriott directly beneficially owns 11,585 shares of Common Stock.
- Additionally, Mr. Herriott indirectly holds 1,556 shares in a 401(k) Plan, bringing his total beneficial ownership of Common Stock to 13,141 shares.
- Mr. Herriott also holds an aggregate of 37,434 vested and unvested options to purchase Common Stock and restricted stock units.
Sentiment
Score: 4
Explanation: While the transaction was executed under a pre-arranged 10b5-1 trading plan, insider selling, even planned, can be perceived as a slightly negative signal regarding management's immediate outlook or a move towards diversification rather than a strong vote of confidence.
Positives
- The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than an immediate reaction to new information, which enhances transparency and reduces the perception of opportunistic trading.
Negatives
- Insider selling, even when pre-planned, can sometimes be perceived by the market as a signal of an executive's decision to diversify holdings or a lack of strong conviction in the company's near-term stock performance.
Risks
- NA
Future Outlook
NA
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a routine disclosure requirement for executives of publicly traded companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The transaction was conducted under a Rule 10b5-1 trading plan, which is a corporate governance mechanism allowing insiders to pre-arrange trades to avoid accusations of trading on material non-public information. | 03/03/2025 | Enhances transparency and provides an affirmative defense against insider trading allegations, aligning with best practices in corporate governance for executive stock transactions. |
Stakeholder Impact
- Shareholders may interpret the insider sale, even if pre-planned, as a signal regarding the executive's personal financial strategy or outlook on the company's stock, potentially influencing their own investment decisions.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date Rule 10b5-1 trading plan was entered into. |
| 11/19/2025 | Date of the reported transaction (sale of common stock). |
| 11/21/2025 | Date the Form 4 was signed by attorney-in-fact. |
Recommendation
holdThe sale of shares by a senior executive, while executed under a pre-arranged 10b5-1 trading plan, is generally not a strong positive signal. However, the pre-planned nature mitigates the immediate negative interpretation. This single transaction is unlikely to significantly alter the fundamental investment thesis for Exact Sciences, warranting a 'hold' recommendation based solely on this filing.
Keywords
EXAS, Exact Sciences, insider trading, Form 4, stock sale, James Herriott, 10b5-1 plan, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.